Developing a risk assessment tool for discriminating social cognition deficits in dementia from that of depressionTo look at the differences in "social cognition"-the ability to look at the interpret the social world and put yourself in someone else's shoes-between people with depression,people with frontotemporal dementia, and healthy controls. Recruiting Principal Investigator Howard FeldmanBody Locations and Systems Dementia, DepressionArea VancouverAge 40-80
Reshaping the Path of Vascular Cognitive Impairment (VCI)The investigators will conduct a proof-of-concept randomized controlled trial study to provide preliminary evidence of efficacy of a resistance exercise training program for maintaining white matter integrity and improving cognitive function in older adults with vascular cognitive impairment, comRecruiting Principal Investigator Teresa Liu-AmbroseArea VancouverAge 55 and above
Clinical dAta, NAtural language pRocessing and eYe tracking for dementia risk stratification (CANARY)Research has shown that Alzheimer’s disease can cause changes in a person’s speech and eye-movements. As neurodegeneration progresses, gaze and language pathways are disrupted.Recruiting Principal Investigator Thalia FieldBody Locations and Systems DementiaArea VancouverAge 19 and above
Characterization of Dementia Due to Mixed Alzheimer and Subcortical Vascular Pathology The purpose of this study is to determine the clinical, cognitive, motor, brain imaging, genetic and biochemical biomarker characteristics of Alzheimer disease (AD), subcortical vascular disease (SVaD) and mixed dementia (AD + sVaD). Closed for Recruitment Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, DementiaArea Vancouver
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at…The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of gantenerumab and solanezumab in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves cognitive outcomes and disease-relatClosed for Recruitment Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, Neurologic Diseases, DementiaArea VancouverAge 18-80
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237. Closed for Recruitment Principal Investigator Ging-Yuek Robin HsiungBody Locations and Systems Alzheimer's Disease, DementiaArea Vancouver
